IP Library › Granted Patent US 7,615,219
Granted Patent B2
US 7,615,219 · App. 10/542,238 · Granted Nov 10, 2009

Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia

Assignee: Life Sciences Research Partners VZW
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,615,219
App. No.
10/542,238
Granted
Nov 10, 2009
Kind
B2
Abstract

The present invention discloses the use of inhibitors and/or antagonists of PACAP signalling for the manufacture of a medicament for the prevention or treatment of decreased blood platelet numbers (thrombocytopenia).

Claims (7)

1. A method of treating thrombocytopenia in a subject having thrombocytopenia, said method comprising the step of administering to said subject a compound inhibiting PACAP activity, wherein said compound inhibiting PACAP activity is a neutralizing anti-PACAP antibody or an antigen-binding fragment thereof.

2. The method of claim 1 , wherein said neutralizing antibody or antigen binding fragment inhibits mature PACAP or an isoform thereof.

3. The method according to claim 1 , wherein said thrombocytopenia is infection-induced thrombocytopenia or treatment-induced thrombocytopenia.

4. The method according to claim 1 wherein said neutralizing anti-PACAP antibody or antigen-binding fragment thereof, is capable of binding to the PACAP(1-38) polypeptide consisting of the amino acid sequence of SEQ ID NO:1.

5. A method of lowering the risk of acquiring or developing thrombocytopenia in a subject having a high probability of acquiring or developing thrombocytopenia, said method comprising the step of administering to said subject a compound inhibiting PACAP activity wherein said compound inhibiting PACAP activity is a neutralizing anti-PACAP antibody or an antigen-binding fragment thereof.

6. The method according to claim 5 , wherein said subject has cancer and wherein said compound is adminstered prior or during chemotherapy.

7. The method according to claim 5 , wherein said subject is at risk of developing infection-induced thrombocytopenia.

Assignments (2)
CHANGE OF NAME Recorded Sep 24, 2009
From: D. COLLEN RESEARCH FOUNDATION VZW
To: LIFE SCIENCES RESEARCH PARTNERS VZW
Reel/Frame 023279/0103 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2006
From: FRESON, KATHLEEN; VAN GEET, CHRIS; HOYLAERTS, MARC
To: D. COLLEN RESEARCH FOUNDATION VZW
Reel/Frame 017007/0523 →
Priority Claims (3)
GB 0300934.7 · Jan 16, 2003 · national
GB 0307667.6 · Apr 3, 2003 · national
GB 0310037.7 · Apr 3, 2003 · national
Continuity (1)
Related Publication 20060062785A1 · Mar 23, 2006